Australian Clinical Labs Ltd (ACL) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Australian Clinical Labs Ltd stock A$2.80, price A$3.22, that is 13.0% below the price, quality 67 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range A$1.84 – A$4.79 · fair‑value band A$2.10 – A$3.90 · the A$3.22 price screens above the A$2.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Australian Clinical Labs in your weekly email
Every Wednesday you see whether Australian Clinical Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Australian Clinical Labs Limited provides pathology diagnostic services in Australia.
Show moreShow less
The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs.
It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
Stock analysis
Australian Clinical Labs Ltd (ACL) currently trades at A$3.22, while our model-based Fair Value estimate is A$2.80, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of A$10.60 per share, and 12 of the 24 models we run sit above the A$3.22 price.
Bear case: the Earnings-Based group reads lowest at A$1.56, and 12 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: A$2.10 (bear) to A$3.90 (bull), the price of A$3.22 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Australian Clinical Labs Ltd reported revenue of A$730M in FY2026 versus A$989M in FY2022, a compound −7.3%/yr. Reported net income was A$23.7M in FY2026, compounding −39.6%/yr from FY2022.
Key figures
Market cap A$617M (≈ $425M) Small · P/E ratio 26.8 · P/S ratio 0.84 · EPS (TTM) A$0.1200 · Dividend yield 4.0% · Net margin 3.2% · Return on equity 14.9% · Return on assets (EBIT) 23.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −13%, ACL screens richer than that median.
Fair Value models
BearA$2.10Fair Value A$2.80BullA$3.90
Price A$3.22 · Downside -13.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−16.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.8%
Dividend (yield on the price)4.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 8%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−17.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about −19.6% a year for the price and +0.6% for the forecasts.
Compare Australian Clinical Labs Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−13.0% · Above median
Profitability
Return on equity (12 months)14.9% · Top 25%
Return on assets4.0% · Above median
Net margin (12 months)3.2% · Below median
Operating margin (12 months)11.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−0.4% · Below median
Dividend yield (12 months)4.0% · Top 25%
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)26.8× · Cheaper than median
P/B4.13× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Australian Clinical Labs Ltd (ACL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of A$2.80 versus a price of A$3.22, about 13% lower (overvalued).
What is the fair value of ACL?
Our model-based fair value for Australian Clinical Labs Ltd is A$2.80 (as of Nov 8, 2026), built from audited fundamentals. The current price: A$3.22.
What is the quality score of ACL?
Australian Clinical Labs Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Australian Clinical Labs Ltd (ACL)?
Our model-based price target is the fair value of A$2.80 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario A$2.10, optimistic scenario A$3.90. It is a calculation from audited fundamentals, not an analyst target.
What is the Australian Clinical Labs Ltd stock forecast for 2026?
Our models put fair value at A$2.80, about 13% lower versus a price of A$3.22 (overvalued). Cautious scenario A$2.10, optimistic scenario A$3.90. The calculation is refreshed regularly with new filings.
What is the revenue of Australian Clinical Labs Ltd (ACL)?
Australian Clinical Labs Ltd reported trailing-twelve-month revenue of about A$736M (latest available figure, as of Nov 8, 2026).
Does Australian Clinical Labs Ltd pay a dividend?
Australian Clinical Labs Ltd currently shows a dividend yield of 4.04% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Australian Clinical Labs Ltd (ACL) and when is the ex-dividend date?
Australian Clinical Labs Ltd pays a dividend of A$0.13 per share a year, a dividend yield of 4.0%. The last ex-dividend date was Sep 2, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 108% of earnings. Free cash flow covers the dividend 6.34 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Australian Clinical Labs Ltd (ACL)?
For today's price to be fair in a discounted-cash-flow model, Australian Clinical Labs Ltd would have to grow free cash flow by -17.2 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.6 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of ACL use?
Our models discount Australian Clinical Labs Ltd at 10.5 %: a base by market capitalisation (small), damped by beta 0.82, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Australian Clinical Labs Ltd that is -17.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Australian Clinical Labs Ltd (ACL) delivered so far?
Over the past 5 years revenue at Australian Clinical Labs Ltd grew +2.6 % a year. The price currently implies free-cash-flow growth of -17.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Australian Clinical Labs Ltd (ACL) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Australian Clinical Labs Ltd (-17.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Australian Clinical Labs Ltd (ACL)?
The free-cash-flow yield on the price is 24.92 %: that much free cash flow Australian Clinical Labs Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Australian Clinical Labs Ltd (ACL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Australian Clinical Labs Ltd it is A$2.80 per share (as of Nov 8, 2026), against a price of A$3.22. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Australian Clinical Labs Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ACL trades above its calculated fair value: price A$3.22, fair value A$2.80, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACL?
No. The price is what the market pays today (A$3.22); the fair value is what the company's own numbers justify (A$2.80). For Australian Clinical Labs Ltd the two are A$0.4200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Australian Clinical Labs Ltd worth?
The market values Australian Clinical Labs Ltd at about A$617M (market capitalisation, as of Nov 8, 2026). Per share that is A$3.22; our models calculate a fair value of A$2.80 per share.
What do the bullish and bearish scenarios say about ACL?
Our models span a range for Australian Clinical Labs Ltd: cautious scenario A$2.10, base A$2.80, optimistic A$3.90 per share (as of Nov 8, 2026, price A$3.22). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ACL?
Australian Clinical Labs Ltd trades at a price-to-earnings ratio of 26.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$2.80 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2021 to 2026), reported earnings: 17.2. Other multiples: P/B 4.1, P/S 0.8, EV/EBITDA 8.0.
How solid is the balance sheet of Australian Clinical Labs Ltd (ACL)?
Balance-sheet figures for Australian Clinical Labs Ltd (as of Nov 8, 2026): return on equity 14.9%, debt of 0.42 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is ACL from its 52-week high?
Australian Clinical Labs Ltd trades at A$3.22, about 2% below its 52-week high of A$3.30 and 75% above the low of A$1.84 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$2.80 is for.
Which stocks are comparable to Australian Clinical Labs Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Australian Clinical Labs Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price A$3.22, calculated fair value A$2.80 (−13%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACL calculated?
We run Australian Clinical Labs Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$2.80 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Australian Clinical Labs Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Australian Clinical Labs Ltd (ACL)?
The closing price on Nov 9, 2026 was A$3.22. Our model-based fair value is A$2.80, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Australian Clinical Labs Ltd right now?
Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (A$2.10 to A$3.90) leaves room in how you read the outcome.
Key figures of Australian Clinical Labs Ltd
How large is the market capitalisation of Australian Clinical Labs Ltd (ACL)?
The market capitalisation of Australian Clinical Labs Ltd is A$617M (≈ $425M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Australian Clinical Labs Ltd (ACL)?
The price-to-sales ratio of Australian Clinical Labs Ltd is 0.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Australian Clinical Labs Ltd (ACL)?
Earnings per share at Australian Clinical Labs Ltd are A$0.1200 (price ÷ EPS = P/E 26.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Australian Clinical Labs Ltd (ACL)?
The dividend yield of Australian Clinical Labs Ltd is 4.0% (payout 108%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Australian Clinical Labs Ltd (ACL)?
The net margin of Australian Clinical Labs Ltd is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Australian Clinical Labs Ltd (ACL)?
The return on equity (ROE) of Australian Clinical Labs Ltd is 14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Australian Clinical Labs Ltd (ACL)?
On an EBIT basis the return on assets of Australian Clinical Labs Ltd is 23.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Australian Clinical Labs Ltd (ACL)?
The operating margin of Australian Clinical Labs Ltd is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Australian Clinical Labs Ltd (ACL)?
Revenue at Australian Clinical Labs Ltd is growing −0.4% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Australian Clinical Labs Ltd (ACL)?
Earnings per share at Australian Clinical Labs Ltd are growing −8.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Australian Clinical Labs Ltd (ACL) carry?
The net debt of Australian Clinical Labs Ltd is A$313M (fiscal year 2026, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Australian Clinical Labs Ltd in the live analysis
One click puts Australian Clinical Labs Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026